RxDoctor Payments Data

Ankit Dubey, MD

Internal Medicine · Fairfield, CANPI 1275191249

Payments from drug & device makers

$931in general payments, 2019–2025

Across 13 payments — averaging $71.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$371
  • GSK$124
  • AbbVie$117
  • Lilly USA, LLC$113
  • Astellas Pharma US Inc$90
  • Exact Sciences$56
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$931 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$182,670
Medicare patients
331
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$90,532
JardianceEmpagliflozin69$89,400
RybelsusSemaglutide23$46,590
EliquisApixaban17$22,093
JanuviaSitagliptin Phosphate13$19,045
FarxigaDapagliflozin Propanediol17$16,158
MounjaroTirzepatide12$13,369
MyrbetriqMirabegron11$8,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,133
Celecoxib21$4,107
Atorvastatin Calcium294$2,592
Duloxetine Hcl32$1,810
Rosuvastatin Calcium93$1,762
Diclofenac Sodium38$1,538
Gabapentin67$1,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$371$137,12284 claims
MerckJanuvia$25$19,04513 claims
Lilly USA, LLCMounjaro$113$13,36912 claims
Astellas Pharma US IncMyrbetriq$90$8,25111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →